Clinical Trial News and Research

RSS

URMC research confirms possible use of mifepristone for painful fibroids

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

8 Mar 2011

First western U.S. hand transplant surgery performed at UCLA Medical Center

Surgeons at Ronald Reagan UCLA Medical Center performed the first hand transplant in the western United States in an operation that began one minute before midnight on Friday, March 4, and was completed 14-and-a-half hours later, on Saturday, March 5.

8 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Repligen Corporation announced today results of a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

8 Mar 2011

New discovery can provide insight into lung cancer

A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease.

8 Mar 2011

NanoLogix announces MRSA testing preliminary results, new Science Advisory Board members at UTHSC

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell microorganisms, announces preliminary results of MRSA testing at the University of Texas Health Science Center - Houston. Dr. Jonathan Faro, M.D., Ph.D. has found NanoLogix technology is able to deliver results for MRSA in 6 hours, as opposed to conventional culture-based testing wait times of 24 to 48 hours.

7 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Starting rehabilitation sooner following knee arthroplasty surgery could pay dividends - for both patients and hospitals. Commencing physical therapy within 24 hours of surgery can improve pain, range of joint motion and muscle strength as well as cut hospital stays, according to new research in the journal Clinical Rehabilitation, published by SAGE.

6 Mar 2011

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Medifocus Inc. is pleased to announce that two clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

5 Mar 2011

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative.

5 Mar 2011

Researchers use qMRI to confirm effect of CS treatment in patients with OA

A group of Canadian researchers led by Prof. Jean-Pierre Pelletier, Head of the Osteoarthritis Research Unit at the University of Montreal Hospital Research Centre, published a clinical trial in which they confirm, for the first time using quantitative Magnetic Resonance Imaging, the disease modifying effects of chondroitin sulphate, a symptomatic slow acting drug for osteoarthritis.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented today.

4 Mar 2011

Miracor completes PICSO System pilot study in patients with ACS

Miracor Medical Systems GmbH announced today the successful completion of the pilot study of its PICSO System, designed to improve acute coronary syndrome revascularization following primary percutaneous coronary intervention.

4 Mar 2011

President's bioethics commission names international panel to review whether U.S. rules protect clinical trial participants in U.S., abroad

"Prompted by concerns about an unethical U.S.-sponsored study in the 1940s," the Presidential Commission for the Study of Bioethical Issues on Tuesday announced the formation of an international panel "that will examine whether current rules adequately protect volunteers in global clinical trials," Science's "ScienceInsider" blog reports.

4 Mar 2011

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.

4 Mar 2011

Clinical Trial News and Research

URMC research confirms possible use of mifepristone for painful fibroids

First western U.S. hand transplant surgery performed at UCLA Medical Center

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

New discovery can provide insight into lung cancer

NanoLogix announces MRSA testing preliminary results, new Science Advisory Board members at UTHSC

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Scientists identify regulatory T cells responsible for limiting immune response

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

FDA approves change to prescribing information for Gilead Sciences' Letairis

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Researchers use qMRI to confirm effect of CS treatment in patients with OA

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Miracor completes PICSO System pilot study in patients with ACS

President's bioethics commission names international panel to review whether U.S. rules protect clinical trial participants in U.S., abroad

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News